Related Experiment Videos
Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.
T Kilicarslan1, R L Haining, A E Rettie
1Department of Pharmacology, University of Toronto, Toronto, Canada.
Summary
Cytochrome P450 enzymes CYP2C19 and CYP3A4 are key to flunitrazepam metabolism. CYP2C19 primarily drives demethylation, impacting drug efficacy and safety, while CYP3A4 is crucial for 3-hydroxylation.
Area of Science:
- Pharmacology
- Drug Metabolism
- Biochemistry
Background:
- Flunitrazepam is metabolized in the body.
- Understanding its metabolic pathways is crucial for drug safety and efficacy.
Purpose of the Study:
- To identify the specific cytochrome P450 (CYP) enzymes responsible for flunitrazepam metabolism.
- To quantify the contribution of these enzymes to the formation of major flunitrazepam metabolites.
Main Methods:
- Incubation of flunitrazepam with human liver microsomes.
- Enzyme kinetic studies using varying substrate concentrations.
- Inhibition studies using specific CYP inhibitors (S-mephenytoin, ketoconazole) and antibodies against CYP2C19 and CYP3A4.
Main Results:
- CYP2C19 and CYP3A4 were identified as the primary enzymes metabolizing flunitrazepam.
- CYP2C19 predominantly mediated desmethylflunitrazepam formation, while CYP3A4 was mainly responsible for 3-hydroxyflunitrazepam formation.
- In vivo, CYP2C19 accounts for approximately 63% of desmethylflunitrazepam formation at therapeutic concentrations.
Conclusions:
- CYP2C19 plays a significant role in flunitrazepam demethylation, potentially affecting drug efficacy and safety due to its polymorphic nature.
- CYP3A4 is the main enzyme responsible for the formation of the 3-hydroxyflunitrazepam metabolite.